Tavros is also leveraging its proprietary platform and map of useful synthetic lethal relationships to build a pipeline of small-molecule drug candidates. Strategic partnerships with Zentalis Pharmaceuticals, OpenBench, and Vividion Therapeutics have validated the platform and expanded the company’s clinical impact.